Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 11/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20033718 | 0.95 | CYP1A2 (0.42) | CYP1A2SIGMAR1EPHX1EPHX2CNR1 | |
| SCHEMBL19334479 | 0.93 | CYP1A2 (0.41) | CYP1A2SIGMAR1EPHX1EPHX2CNR1 | |
| SCHEMBL19983332 | 0.93 | CYP1A2 (0.43) | CYP1A2SIGMAR1EPHX1EPHX2CNR1 | |
| SCHEMBL20033732 | 0.91 | EPHX1 (0.41) | CYP1A2SIGMAR1EPHX1EPHX2 | |
| SCHEMBL23084775 | 0.90 | CYP1A2 (0.42) | CYP1A2SIGMAR1EPHX1EPHX2CNR1 | |
| SCHEMBL25007273 | 0.89 | CYP1A2 (0.37) | CYP1A2SIGMAR1EPHX1EPHX2 | |
| SCHEMBL23084769 | 0.88 | CYP1A2 (0.39) | CYP1A2SIGMAR1EPHX1EPHX2CNR1 | |
| SCHEMBL21166023 | 0.88 | CYP1A2 (0.39) | CYP1A2SIGMAR1EPHX1EPHX2CNR1 | |
| SCHEMBL22778636 | 0.87 | GNAO1 (0.39) | CYP1A2EPHX1CNR1CCR2 | |
| SCHEMBL22752273 | 0.87 | GNAO1 (0.39) | CYP1A2EPHX1CNR1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CYP1A2 1148/4885SIGMAR1 1660/4885EPHX1 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.